| Bid | 6.02 |
| Market Cap | 1.95B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.52 |
| PE Ratio (ttm) | -9.74 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 19.17 |
| Volume | 269,889 |
| Avg. Volume (20D) | 552,485 |
| Open | 15.33 |
| Previous Close | 15.26 |
| Day's Range | 14.44 - 15.47 |
| 52-Week Range | 6.95 - 18.97 |
| Beta | undefined |
About CNTA
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatm...
Analyst Forecast
According to 7 analyst ratings, the average rating for CNTA stock is "Buy." The 12-month stock price forecast is $27, which is an increase of 82.31% from the latest price.
2 weeks ago · seekingalpha.com
Centessa: Shift In Focus With ORX750 Development Continues To Pay OffCentessa Pharmaceuticals shelved its SerpinPC candidate, which was being used to treat patients with Hemophilia B; Established net savings of $200 million because of this move. Positive interim and fi...